HRA014006
Title:
Role of EZH2 crotonylation in breast cancer metastsis
Release date:
2025-10-28
Description:
EZH2 is overexpressed in breast cancer and many other kinds of cancers. Its expression is correlated to the outcomes in patients with cancer. Disruption of the stability of EZH2 protein is an effective therapeutic strategy. In this project, EZH2 was found to be crotonylated, which resulted in the shortened half-life of EZH2 and decreased stability. After the treatment of crotonic acid, histone acetyltransferase p300 induced crotonylation at the K318 site of EZH2. The level of crotonylated EZH2 was higher in normal breast epithelial cells than that in breast cancer cells.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Cell line related study
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
YY_rawdata
Contact person:
Yu Yu
Email:
yuyu@bjmu.edu.cn
Description:
YY_rawdata
Individuals & samples
Submitter:   Yu Yu / yuyu@bjmu.edu.cn
Organization:   Peking University Health Science Center
Submission date:   2025-10-21
Requests:   1